Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005629 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Liver Cancer
A Phase 1 study of Liver Cancer, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT00005629: Completed Phase 1 study of Liver Cancer, sponsored by Jonsson Comprehensive Cancer Center.
NCT00005629 is a Phase 1 study of Liver Cancer that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 6 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005629, a Phase 1 study of Liver Cancer, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have liver cancer.
Primary Outcome
Determine the safety of intradermal injection of the hAFP137-145 (PLFQVPEPV), hAFP158-166 (FMNKFIYEI), hAFP325-334 (GLSPNLNRFL) and hAFP542-550 (GVALQTMKQ) peptides emulsified in Montanide ISA-51.
Conditions Studied
Interventions
- BIOLOGICAL AFP gene hepatocellular carcinoma vaccine
Study Locations (1)
California
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 1999-07 |
| Est. Completion | 2002-06 |
| Phase | Phase 1 |
What the finished NCT00005629 record still lists
NCT00005629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which AFP gene hepatocellular carcinoma vaccine is the first listed.
NCT00005629 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00005629 about?
NCT00005629 is a clinical study titled "Vaccine Therapy in Treating Patients With Liver Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have liver cancer.
What is the current status of trial NCT00005629?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 1999-07. Estimated completion is 2002-06.
What conditions does trial NCT00005629 study?
This clinical trial studies the following conditions: Liver Cancer.
What interventions are being tested in trial NCT00005629?
The interventions under investigation include: AFP gene hepatocellular carcinoma vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005629?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005629 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00005629's enrollment target sits among peer trials
6 77th of 78 higher than 2 of 78 other Liver Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
RECRUITING · Phase 1
-
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
RECRUITING · Phase 1
-
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
ACTIVE NOT RECRUITING · Phase 1
-
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia